英国国家卫生与保健评价研究院推荐3款新型丙型肝炎治疗药

ipsvirus

英国国家卫生与保健评价研究院(NICE) 29日发布治疗指南，向慢性丙型肝炎患者推荐了3款新型治疗药物：

●百时美施贵宝的Daklinza(daclatasvir)

●吉利德的Harvoni(复方sofosbuvir和ledipasvir)

●艾伯维的Viekirax(复方Ombitasvir-paritaprevir-ritonavir)或者Viekira/Exviera（复方Ombitasvir-paritaprevir-ritonavir-dasabuvir）

丙型肝炎（hepatitis C）是一种由丙型肝炎病毒(HCV)感染所引起的疾病，主要经过血液传播，可引起肝脏炎症及损害，导致肝功能异常。大约1/3的感染者会逐渐发展成肝硬化，严重者甚至发展成肝癌。

NICE卫生技术评估中心主任Carole Longson教授表示：丙型肝炎或已成为人类健康的一大挑战。由于诊断技术不足，目前英国大约有50%的感染者尚未被确诊。而被确诊的患者在接受干扰素治疗时，治疗过程的出现各种不良反应，致使病人依从性较差，不遵医嘱接受规范治疗。

Carole Longson教授感慨：“这一份治疗指南的发布，不仅是为患者提供了更多临床用药选择，也离人类终结丙型肝炎感染目标更近了一步。”

指南中还提到，患者可持医疗院所所开具的的处方意见，通过英国全民健康服务体系（NHS）的特殊委托程序获得丙肝治疗药物，由此保证患者在第一时间获得优先治疗权利。

（生物谷Bioon.com）

ipsvirus

NICE recommends three new treatments for hepatitis C in draft guidance

The UK National Institute for Health and Care Excellence (NICE) has published draft guidance recommending three different treatment options for some people with hepatitis C.

For the treatment of chronic hepatitis C, the NICE drafts recommend:

Bristol-Myers Squibb’s Daklinza (Daclatasvir)
Gilead’s Harvoni (Ledipasvir-sofosbuvir)
Abbvie’s Viekirax with or without Exviera (Ombitasvir-paritaprevir-ritonavir with or without dasabuvir)
Hepatitis C is a virus that infects the liver. It is spread by contact with infected blood, for instance by using contaminated needles for injecting drugs or sharing razors or toothbrushes. The virus can cause inflammation of, and damage to the liver, preventing it from working properly.

About a third of people infected with the hepatitis C virus will eventually develop liver cirrhosis, where normal liver tissue is replaced by scar tissue. A small number of people with chronic hepatitis C and cirrhosis also go on to develop liver cancer.

Hepatitis C a “major public health challenge”

Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said, “Hepatitis C is a major public health challenge. It is difficult to diagnose, with estimates suggesting around 50% of people with the condition in England remain undiagnosed. But even when people are diagnosed, the long duration and potentially unpleasant side-effects of current interferon-based treatments can discourage people with the disease from completing the full course, or even from seeking treatment in the first place.

“We are very pleased to recommend not only one, but three new treatment options for chronic hepatitis C. This is good news, not just for people with chronic hepatitis C, but also because having more effective treatments for the condition could reduce the spread of the virus.”

It is recommended that access to the drugs used to treat hepatitis C is managed through the specialised commissioning programme put in place by NHS England with prescribing decisions made by multidisciplinary teams/centres to ensure that treatment is prioritised for patients with the highest unmet clinical need.

http://www.europeanpharmaceutica ... -in-draft-guidance/